

Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Â FORM 6-K
Â Â Â Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934Â Date
of Report: January 22, 2025Â Commission File Number: 001-39307 Â Â Â Legend Biotech Corporation (Exact Name of
Registrant as Specified in its Charter) Â Â Â 2101 Cottontail Lane Somerset, New Jersey 08873 (Address of principal
executive office) Â Â Â Indicate by check mark whether the registrant files or will file annualreports under cover of
Form 20-F or Form 40-F:Â Form 20-FÂ Â ~Â Â Â Â Â Â Â Form40-FÂ Â ~Â Â Â Legend Biotech
Announces Preliminary Sales for CARVYKTIÂ® for the Quarter EndedDecember 31, 2024Â Pursuant to the
Collaboration and License Agreement dated as of December 21, 2017 betweenLegend Biotech Corporation (â€œLegend
Biotechâ€) and Janssen Biotech, Inc. (â€œJanssenâ€), on January22, 2025, Legend Biotech announced that
CARVYKTIÂ® generated approximately \$334 million in net trade sales during the quarterended December 31, 2024.
The net trade sales figure is based on information provided to Legend Biotechby Janssen, and Legend Biotech has not
independently verified the accuracy of such sales figure. Â The sales figure is based on information available to Legend
Biotech as of the dateof this Form 6-K, and the determination of the amount of any revenue or gross profit to be
recorded in Legend Biotechâ€™s consolidatedstatement of operations is subject to completion by management of
Legend Biotech of its financial statements as of and for the periodended December 31, 2024. Legend Biotechâ€™s
independent registered public accountants have not audited, reviewed or performed anyprocedures with respect to this
data and accordingly they have not expressed an opinion or provided any other form of assurance with
respectthereto.Â Cautionary Note Regarding Forward-Looking StatementsÂ Statements in this report on Form 6-K
about future expectations, plans and prospects, as wellas any other statements regarding matters that are not historical
facts, constitute â€œforward-looking statementsâ€ within themeaning of The Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements relatingto CARVYKTIÂ®, including Legend
Biotechâ€™s expectations for net trade sales and resulting gross profit of CARVYKTIÂ®.The words â€œanticipate,â€
â€œbelieve,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€
â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and similar
expressions are intended to identify forward-looking statements,although not all forward-looking statements contain
these identifying words. Actual results may differ materially from those indicatedby such forward-looking statements as
a result of various important factors. Legend Biotechâ€™s expectations could be affected by,among other things,
uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, includingas
a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or
delays,including requests for additional safety and/or efficacy data or analysis of data, or government regulation
generally; unexpected delaysas a result of actions undertaken, or failures to act, by our third party partners;
uncertainties arising from challenges to Legend Biotechâ€™spatent or other proprietary intellectual property
protection, including the uncertainties involved in the U.S. litigation process; competitionin general; government
industry, and general public pricing and other political pressures; as well as the other factors discussed inthe â€œRisk
Factorsâ€ section of the Legend Biotechâ€™s Annual Report on Form 20-F filed with the Securities and
ExchangeCommission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect,actual results may vary materially from those described in this Form 6-K as
anticipated, believed, estimated or expected. Any forward-lookingstatements contained in this Form 6-K speak only as
of the date of this Form 6-K. Legend Biotech specifically disclaims any obligationto update any forward-looking
statement, whether as a result of new information, future events or otherwise.Â This report on Form 6-K is
herebyincorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-
278050, 333-272222 and333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by
documentsor reports subsequently filed.Â Â Â SIGNATURESÂ Pursuant to the requirements of the Securities
Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.Â Â Â LEGEND BIOTECH CORPORATION Â Â Â Date:Â January 22, 2025 Â By: /s/
Ying Huang Â Â Name: Ying Huang, Ph.D. Â Â Title: Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â